Video

Visibility and Risk Management with Overhaul

Author(s):

Amy Shortman

Amy Shortman, Overhaul, explains the importance of visibility for risk management and compliance issues when navigating the supply chain and highlights solutions to support life sciences.

Newsletter

Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.

Subscribe Now!
Related Videos
Related Content
How Life Sciences Firms Are Evolving to Navigate Trade, Tariff, and Pricing Turbulence
July 25th 2025

How Life Sciences Firms Are Evolving to Navigate Trade, Tariff, and Pricing Turbulence

Nicholas Saraceno, Editor
As new pricing and trade policies take shape, 60% of life sciences and healthcare executives anticipate business disruption, according to a new survey from Deloitte.
How Recent Executive Orders Impact the Drug Pricing Landscape
May 30th 2025

How Recent Executive Orders Impact the Drug Pricing Landscape

Nicholas Saraceno, Editor
Alice Valder Curran outlines the steps manufacturers should take to better prepare for upcoming executive actions on drug pricing and market access.
Recapping the Sarepta Saga—And Implications for Industry
July 24th 2025

Recapping the Sarepta Saga—And Implications for Industry

Michael Christel
A timeline of key developments surrounding Sarepta Therapeutics' Duchenne muscular dystrophy drug Elevidys, and the potential future impacts for gene therapy regulation and market access.
Selecting the Right 3PL
February 28th 2025

Selecting the Right 3PL

Nicholas Saraceno, Editor
Tracy Lopez uncovers the fundamentals pertaining to third-party logistics providers.
AstraZeneca Commits $50 Billion to US Manufacturing and R&D Efforts by 2030
July 22nd 2025

AstraZeneca Commits $50 Billion to US Manufacturing and R&D Efforts by 2030

Nicholas Saraceno, Editor
The investment is highlighted by a state-of-the-art API facility in Virginia and expansions across multiple states.
Trump Says Pharma Industry Should Expect Tariffs by Aug. 1
July 17th 2025

Trump Says Pharma Industry Should Expect Tariffs by Aug. 1

Nicholas Saraceno, Editor
Pharma prepares for looming tariffs, as the US president signals a phased increase starting Aug. 1, but the official starting tax rate is yet to be determined.
© 2025 MJH Life Sciences

All rights reserved.